GPC3 and neoplasm: Emerging immunotherapeutic strategies including GPC3-directed CAR-T cells and monoclonal antibodies (e.g., codrituzumab) have shown preclinical promise, yet face clinical translation barriers including inadequate tumor infiltration of effector cells and tumor microenvironment-mediated immunosuppression (8–10).